Vascular effects of PPAR  activation: Inflammation.

Slides:

Advertisements

Similar presentations

Metabolic Syndrome and Obesity in Peripheral Arterial Disease

Advertisements

Walter Lab: Gut microbiome and its interactions with metabolic disease

Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.

PPAR  activation Impact on pathways of clinical care.

Ian Graham et al. European Heart Journal 2007;28:

Diabetes Mellitus Type 2

Targeting Insulin Resistance for Vascular Protection.

VBWG Potential role of PPAR activation in CV risk reduction Adapted from Tenenbaum A et al. Intl J Cardiol. 2004;97: Atherosclerosis Insulin resistance.

Effects of Low-Fat Dairy Consumption on Markers of Low- Grade Systemic Inflammation and Endothelial Function in Overweight and Obese Subjects: An Intervention.

Hypothesis The generation of pro-oxidants secondary to abnormal placental perfusion interacts with maternal constitutional factors to generate oxidative.

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 1 Arginine Cardio: Evidence-based reduction of blood pressure (1) L-Arginine is the precursor.

Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.

Hyperglycemia at the Vessel Wall. Potential hyperglycemia-induced tissue damage Brownlee M. Diabetes. 2005;54: Repeated acute changes in cellular.

Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Secondhand smoke exposure in children - focus on the cardiovascular system Your name, institution, etc. here YOUR LOGO HERE (can paste to each slide)

Inflammatory Markers, Pharmacotherapy, and Clinical Trials Paul M. Ridker, M.D., M.P.H., and Christie M. Ballantyne, M.D.

Vascular effects of PPAR  activation: Endothelial function.

VBWG Insulin Sensitizers: Surrogate and Clinical Outcomes Studies.

cardio protection: Focus on

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stanley Schwartz.

CV Risk Reduction, Diabetes Prevention, and TZDs.

Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.

VBWG Insulin Resistance and Cardiovascular Disease: New Perspectives From Vascular Biology.

Glycemic Control: When the Lower is Not the “Better”?

PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.

STEVIA SYMPOSIUM LEUVEN July 2009 EFFECT OF STEVIOSIDE ON ATHEROSCLEROSIS IN A MOUSE MODEL OF THE METABOLIC SYNDROME Paul Holvoet Atherosclerosis and Metabolism.

PPAR gamma system and glucose: metabolism. Shared metabolic abnormalities with insulin resistance and endothelial dysfunction Glucotoxicity Lipotoxicity.

Plasminogen-Activating Inhibitor-1 (PAI-1) High PAI-1 associated with: Obesity (especially visceral), possible fatty liver. 2,3,4 Inflammation and oxidative.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.69 ( ) n=13 (16,228/11,279)

Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C

General features of insulin signal transduction pathways Jeong-a Kim, et al. Circulation 2006;113:

Insulin Resistance Progression to Diabetes Part 3.

Framingham and the Muddy Waters Jeffry N. Gerber, MD Denver’s Diet Doctor.

Carina Signori, D.O., M.P.H. Penn State Hershey Medical Center Ceriello, Antonio. Diabetes Care August 2010;33,8.

Source: International Chair on Cardiometabolic Risk Metabolic Syndrome and Adipose Tissue Yuji Matsuzawa, MD, PhD Director.

J Clin Endocrinol Metab, Sep 2006, 91(9):

GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.

Abstract The metabolic syndrome (MetS) has surpassed smoking as the number one cause of cardiovascular deaths in the US. However, it remains under diagnosed.

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

Targets for Therapies/ New Guidelines

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

Titel The impact of combined exercise programme in prediabetic, overweight or high risk individuals By Bandar Alharbi 1.

APOC3 LOF heterozygotes have lower IVD and IHD risks due to lower RC

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

Arterioscler Thromb Vasc Biol

Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.

New Insights on PPAR Agonists For Cardiovascular Disease

The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.

Emerging Mechanisms in Glucose Metabolism

In Metabolic Syndrome Hyperinsulinism Creates the Vicious Cycle: Increased MAP-kinase pathway Circulation. 2005;111: Metabolic Syndrome A Comprehensive.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Trial profile John A Dormandy et al. Lancet 2005;366:

UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

The Cardiovascular Biology of Glucagon-like Peptide-1

Learning Objectives Metabolic Abnormalities Associated With T2D.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

The Cardiovascular Biology of Glucagon-like Peptide-1

Characteristics of SIRCA Participants

Adiponectin hypothesis for insulin resistance, the metabolic syndrome, and atherosclerosis Takashi Kadowaki, et al. J. Clin. Invest :

The adiponectin paradox.

Sulphonylureas and Glitazones In spite of the big number of anti-diabetic factors obtainable.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Presentation transcript:

Vascular effects of PPAR  activation: Inflammation

Campia U et al. Circulation. 2006;113: Pioglitazone improves endothelial vasodilation and decreases inflammation Forearm blood flow (%  from baseline) after 16 wks N = 80 with hypertension or hypercholesterolemia and no diabetes Pioglitazone 45 mg/d Placebo Bradykinin (ng/min) All subjects Insulin resistant Insulin sensitive CRP (mg/L) P = P = 0.38 P = P = P = 0.41 P = 0.02

PPAR  agonists impact inflammatory markers and adiponectin N = 54 adults with metabolic syndrome and no diabetes Samaha FF et al. Arterioscler Thromb Vasc Biol. 2006;26: *P = 0.002; † P = 0.027; ‡ P < Change from baseline after 12 weeks (%) * † ‡ PlaceboRosiglitazone 8 mg/d IL-6CRP Adiponectin

Surrogate outcome results driving major TZD trials TZDs are associated with reductions in atherosclerotic progression and restenosis TZDs reduce inflammatory markers (CRP, TNF  ) independent of glycemic control Reducing CV risk factors with TZDs may also reduce CV morbidity and mortality Dormandy JA et al. Lancet. 2005;366: